FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2015
Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 

 
ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2015
 
Results of Annual General Meeting held on 24 April 2015
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 12 were passed as special resolutions.
 
 
RESOLUTION
VOTES FOR
% OF VOTES CAST
VOTES AGAINST
% OF VOTES CAST
VOTES CAST IN TOTAL
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
VOTES WITHHELD

1

To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2014
877,576,463
99.67
2,921,581
0.33
880,498,044
69.68%
10,675,935

2

To confirm dividends
886,527,613
99.66
2,986,602
0.34
889,514,215
70.40%
1,659,763

3
 
To re-appoint KPMG LLP, London as Auditor
876,751,815
98.61
12,397,571
1.39
889,149,386
70.37%
2,024,593

4

To authorise the Directors to agree the remuneration of the Auditor
887,495,062
99.82
1,629,520
0.18
889,124,582
70.37%
2,049,398

5a

To re-elect Leif Johansson as a Director
851,461,560
95.76
37,705,142
4.24
889,166,702
70.37%
2,007,277

5b

To re-elect Pascal Soriot as a Director
888,590,119
99.95
426,241
0.05
889,016,360
70.36%
2,157,620

5c

To re-elect Marc Dunoyer as a Director
885,602,969
99.62
3,374,856
0.38
888,977,825
70.36%
2,196,155

5d

To elect Cori Bargmann as a Director
888,638,513
99.96
351,446
0.04
888,989,959
70.36%
2,184,021

5e

To re-elect Geneviève Berger as a Director
888,552,754
99.95
465,106
0.05
889,017,860
70.36%
2,156,120

5f
 
To re-elect Bruce Burlington as a Director
880,639,560
99.88
1,091,107
0.12
881,730,667
69.78%
9,443,312
 
5g

To re-elect Ann Cairns as a Director
888,587,093
99.95
465,731
0.05
889,052,824
70.36%
2,121,156

5h

To re-elect Graham Chipchase as a Director
876,994,757
99.46
4,732,631
0.54
881,727,388
69.78%
9,445,684

5i

To re-elect Jean-Philippe Courtois as a Director
880,585,784
99.87
1,137,760
0.13
881,723,544
69.78%
9,450,753

5j

To re-elect Rudy Markham as a Director
855,335,488
99.27
6,300,712
0.73
861,636,200
68.19%
29,537,348

5k

To re-elect Shriti Vadera as a Director
888,387,120
99.93
582,556
0.07
888,969,676
70.36%
2,204,192

5l

To re-elect Marcus Wallenberg as a Director
846,091,821
98.19
15,599,701
1.81
861,691,522
68.20%
29,482,025

6

To approve the Annual Report on Remuneration for the year ended 31 December 2014
739,049,685
84.11
139,601,566
15.89
878,651,251
69.54%
12,522,725

7

To authorise limited EU political donations
859,081,444
97.36
23,307,997
2.64
882,389,441
69.83%
8,784,535

8

To authorise the Directors to allot shares
808,454,239
91.14
78,551,101
8.86
887,005,340
70.20%
4,168,208

9
 
To authorise the Directors to disapply pre-emption rights
875,263,416
98.61
12,347,679
1.39
887,611,095
70.25%
3,562,455

10

To authorise the Company to purchase its own shares
876,130,644
98.54
13,023,264
1.46
889,153,908
70.37%
2,019,960

11

To reduce the notice period for general meetings
778,280,838
87.53
110,881,255
12.47
889,162,093
70.37%
2,011,885

12

To adopt new Articles of Association
886,456,629
99.90
900,552
0.10
887,357,181
70.23%
3,813,971

Issued capital
As at 22 April 2015, the number of issued shares of the Company was 1,263,544,938, ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

A C N Kemp
Company Secretary
24 April 2015
 

 
SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC




Date: 24 April 2015
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary